Yi-Fei Zhang et al. developed an arginine–glycine–aspartic acid (RGD)-modified liposome, co-encapsulating Dox and CA4 with the aim of assessing sequential release and enhancing tumor inhibition responses. Here, CA4 is linked to neoplasm.